Meningioma involving the superior sagittal sinus: long-term outcome after robotic radiosurgery in primary and recurrent situation

• Published in: Frontiers in oncology 2023-07, Vol.13, p.1206059-1206059
• Main Authors: Schmutzer, Michael, Skrap, Benjamin, Thorsteinsdottir, Jun, Fürweger, Christoph, Muacevic, Alexander, Schichor, Christian
• Format: Article
• Language: English
• Subjects: meningioma; microsurgery; Oncology; robotic radiosurgery; sinus occlusion; superior sagittal sinus
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1206059

Treatment for meningiomas involving the superior sagittal sinus (SSS) is challenging and proved to be associated with higher risks compared to other brain locations. Therapeutical strategies may be either microsurgical (sub-)total resection or adjuvant radiation, or a combination of both. Thrombosis or SSS occlusion following resection or radiosurgery needs to be further elucidated to assess whether single or combined treatment is superior. We here present tumor control and side effect data of robotic radiosurgery (RRS) in combination with or without microsurgery. From our prospective database, we identified 137 patients with WHO grade I meningioma involving the SSS consecutively treated between 2005 and 2020. Treatment decisions were interdisciplinary. Patients underwent RRS as initial/solitary treatment (group 1), as adjuvant treatment after subtotal resection (group 2), or due to recurrent tumor growth after preceding microsurgery (group 3). Positive tumor response was assessed by MRI and defined as reduction of more than 50% of volume. Study endpoints were time to recurrence (TTR), time to RRS, risk factors for decreased survival, and side effects. Overall and specific recurrence rates for treatment groups were analyzed. Side effect data included therapy-related morbidity during follow-up (FU). A total of 137 patients (median age, 58.3 years) with SSS meningiomas WHO grade I were analyzed: 51 patients (37.2%) in group 1, 15 patients (11.0%) in group 2, and 71 patients (51.8%) in group 3. Positive MR (morphological response) to therapy was achieved in 50 patients (36.4%), no response was observed in 25 patients (18.2%), and radiological tumor progression was detected in 8 patients (5.8%). Overall 5-year probability of tumor recurrence was 15.8% (median TTR, 41.6 months). Five-year probabilities of recurrence were 0%, 8.3.%, and 21.5% for groups 1-3 ( = 0.06). In multivariate analysis, tumor volume was significantly associated with extent of SSS occlusion ( = 0.026) and sex ( = 0.011). Tumor volume significantly correlated with TTR ( = 0.0046). Acute sinus venous thrombosis or venous congestion-associated bleedings did not occur in any of the groups. RRS for grade I meningiomas with SSS involvement represents a good option as first-line treatment, occasionally also in recurrent and adjuvant scenarios as part of a multimodal treatment strategy.